ERS 2026: tozorakimab’s groundbreaking exacerbation reduction sets a new bar in COPD
The focus of this latest data presentation was the drug’s efficacy in reducing moderate and severe exacerbations among COPD patients who continued to experience exacerbations despite inhaled standard-of-care therapy.

TrialAssure selected as EMA’s official clinical trial anonymisation partner
ASCO26: AI innovations show promise in reducing the oncology RWD burden
Keeping pace with generative AI in pharmaceutical and healthcare organisations
How wearables can unlock their full potential in clinical research